• In late June 2026, Trevi Therapeutics, Inc. was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth, Russell Microcap, and Russell Microcap Growth benchmarks, reflecting a change in its index eligibility profile.
• This simultaneous loss of multiple index inclusions can alter the mix of institutional holders, affect trading volumes, and reshape how the stock fits into benchmarked portfolios.
• We’ll now examine how Trevi’s removal from several Russell indices may influence its existing investment narrative built around Haduvio’s development.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Trevi Therapeutics Investment Narrative Recap

To own Trevi, you have to believe Haduvio can transition from a single-asset development story into an approved therapy across fibrotic lung cough indications. The key near term catalyst is progress on the planned Phase III program for IPF-related chronic cough, while the biggest risk remains any clinical or regulatory setback around Haduvio’s safety, efficacy or trial design. Trevi’s removal from multiple Russell indices does not directly change these program fundamentals in the short term.

The recent approval to double Trevi’s authorized common shares to 400,000,000 is particularly relevant here, coming shortly after a US$150.8 million follow-on raise. Together, these steps underscore how dependent the Haduvio story is on ongoing access to equity capital to fund parallel late stage trials, which ties back to the risk that future financing, if needed, could materially increase the share count over time.

However, investors should also be aware that if funding needs rise faster than expected, especially after the Russell index removals, then...

Trevi Therapeutics’ narrative projects $12.8 million revenue and $2.5 million earnings by 2029. This requires an earnings increase of about $48 million from -$45.6 million today.

Uncover how Trevi Therapeutics' forecasts yield a $23.90 fair value, a 33% upside to its current price.

Exploring Other Perspectives

Before this index news, the most optimistic analysts were modeling about US$334.8 million of revenue and US$201.3 million of earnings by 2029, so you should recognize how bullish that view is relative to both the clinical execution risks and the possibility that Trevi’s post Russell-removal trading profile could alter how quickly those forecasts might need to be revisited.

Explore 3 other fair value estimates on Trevi Therapeutics - why the stock might be worth as much as 95% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Trevi Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Trevi Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Trevi Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.